Re: Novartis to warn US Doctors on heart risk -

[Guest guest]

At 08:06 AM 10/3/06 -0400, you wrote:

>The risk that physicians switch patients to Sprycel may therefore be

>limited, said Kepler Equities analyst .

>

> " Thus, we leave our Glivec forecasts unchanged for now. However, the news

>increases the risk of a sales growth slow down, " said in a note.

Thanks for posting this important information Cheryl-Anne.

It is amazing that their biggest concern might be a drop in Gleevec sales!!!

C.

[Guest guest]

Hello Cheryl-Anne,

Thank you for the information. It is too bad the U.S. does not have

the equivalent organization of Health Canada. It would seem the best

information on a health risk problem a drug might have, could come

from the bottom line of it's stock performance.

- In , " Cheryl-Anne Simoneau "

<cheryl.simoneau@...> wrote:

>

> Hello ,

>

> Here is the answer to your question:

>

>

> Novartis to warn US doctors on Gleevec heart risks

>

> Tue Oct 3, 2006 4:51am ET 140

<http://i.today.reuters.com/images/spacer.gif>

>

>

>

> [- <javascript:sizeDown();> ] Text <javascript:resetCurrentsize

();> [+

> <javascript:sizeUp();> ]

>

>

> ZURICH, Oct 3 (Reuters) - Swiss drugmaker Novartis (NOVN.VX: Quote

> <http://today.reuters.com/stocks/overview.aspx?

symbol=NOVN.VX & WTmodLoc=InvAr

> t-C1-ArticlePage1> , Profile

> <http://today.reuters.com/stocks/CompanyProfile.aspx?

symbol=NOVN.VX & WTmodLoc

> =InvArt-C1-ArticlePage1> , Research

> <http://today.reuters.com/stocks/ResearchReports.aspx?

symbol=NOVN.VX & WTmodLo

> c=InvArt-C1-ArticlePage1> ) will send a letter to U.S. doctors in

the next

> few days to warn that there is a risk that its cancer drug Gleevec

could

> cause heart damage, a spokesman said.

>

> The letter will contain similar information to one sent to

Canadians warning

> that patients with high blood pressure, diabetes or a history of

heart

> disease who were taking the drug should consult their doctor, said

Novartis

> spokesman Geoff Cook.

>

> " A letter with similar information will be sent to U.S physicians

in the

> next few days, " Cook said in an email to Reuters.

>

> The warnings were sparked by a recent article in Nature Medicine

that said

> the drug, sold in Europe under the name Glivec, could cause

serious heart

> damage.

>

>

> Novartis has said there would be similar warnings in all countries

where the

> product was approved.

>

> The authors of the Nature Medicine article said that similar drugs,

> including Bristol Myers Squibb's (BMY.N: Quote

> <http://today.reuters.com/stocks/overview.aspx?

symbol=BMY.N & WTmodLoc=InvArt-

> C1-ArticlePage1> , Profile

> <http://today.reuters.com/stocks/CompanyProfile.aspx?

symbol=BMY.N & WTmodLoc=I

> nvArt-C1-ArticlePage1> , Research

> <http://today.reuters.com/stocks/ResearchReports.aspx?

symbol=BMY.N & WTmodLoc=

> InvArt-C1-ArticlePage1> ) Sprycel, may suffer from the same safety

problem.

>

> The risk that physicians switch patients to Sprycel may therefore

be

> limited, said Kepler Equities analyst .

>

> " Thus, we leave our Glivec forecasts unchanged for now. However,

the news

> increases the risk of a sales growth slow down, " said in

a note.

>

> C Reuters 2006. .

>

>

>

>